What is Fluxergy?
Fluxergy is a pioneering force in the medical technology sector, specializing in the development of a versatile, multi-modal detection platform. The company's core innovation lies in its ability to miniaturize complex laboratory procedures, effectively bringing high-fidelity molecular testing, immunochemistry, and microscopy—including cytometry—to the point of care. By integrating these diverse testing modalities into a single, automated, sample-to-answer analyzer, Fluxergy is redefining the efficiency of clinical diagnostics. The platform is engineered to detect genes, proteins, small molecules, and cells, offering a comprehensive solution that bridges the gap between centralized laboratory precision and the immediate needs of clinical environments. This technological synthesis positions Fluxergy as a critical player in the evolution of decentralized healthcare delivery.
How much funding has Fluxergy raised?
Fluxergy has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Fluxergy
PPP
Public-Private Partnership
What's next for Fluxergy?
With the recent infusion of capital, Fluxergy is poised to scale its operational capabilities and expand the reach of its diagnostic platform. The strategic focus will likely shift toward optimizing manufacturing workflows and securing regulatory milestones necessary for broader market adoption. As the company transitions from development to commercialization, the emphasis will remain on enhancing the versatility of its automated workflows to meet the evolving demands of global healthcare providers. By leveraging this financing, Fluxergy aims to solidify its market share, ensuring that its multi-modal detection technology becomes a standard component of modern clinical diagnostic toolkits, ultimately driving better patient outcomes through rapid, accurate, and accessible testing.
See full Fluxergy company page
